Christoffer H. Bach

[Matthias Götberg @MGtberg]

@ncurzen @monaltiren @Hragy @JEscaned @BernardBruyne @ColletCarlos @MortonKern @wfearonmd @m1chaella_alex @PCRonline Great question! We were puzzled by this trend and that was prompted us to analyze the 10X larger dataset from Swedeheart showing some interesting differences between iFR and FFR in terms of decision and demographics, but no difference in MACE, death,MI or revasc.

[Christoffer H. Bach @ChrisHBach]

Good News for Intravascular Imaging Continues at 5 Years: RENOVATE-COMPLEX-PCI https://t.co/9MBZrXiMGf

[EuroIntervention @EuroInterventio]

Excimer laser coronary atherectomy is experiencing renewed interest in complex PCI.

This viewpoint revisits the “5 Ss” rule and introduces 3 additional principles to guide contemporary ELCA practice.

https://t.co/JlJYhagdLC
#InterventionalCardiology #PCI #ElCalentao
@JuradoRomanAl @mattiabasile

[Gregg W. Stone MD @GreggWStone]

Our study on outcomes of OCT/IVUS vs. angio guidance of DES in 2005 severely calcified lsns in ECLIPSE publ in JACC CV Int. Img used in 62% (dr discretion) associated with 26% adj decr in TVF. Consistent w/orbital atherectomy or balloon vessel prep. Link https://t.co/x00yLj7JO2

[Gregg W. Stone MD @GreggWStone]

Provocative study from the RENOVATE trialists and Samsung Med Cntr suggesting use of intravascular imaging may eliminate long-term diffs between CABG & PCI. Not definitive absent a powered RCT, but should be enough to mandate IVI in these pts, esp with class I guidelines. Agree?

[EuroIntervention @EuroInterventio]

🎙️ Our new podcast Turning Point launches today!
In Episode 1, Patrick W. Serruys joins host @aayshacader to reflect on a life of bold choices, innovation & mentorship.

🎧 Listen now: https://t.co/dIBTElGu8m

[Salvatore Brugaletta @sbrugaletta]

IVUS is the winner. happy to see that very few are still angio-based. CT will be coming. and surprise about OCT...the ability to measure Ca thickness is not enough? @PCRonline @ColletCarlos @JEscaned @mirvatalasnag

[CVPrevInterv @CVPrevInterv]

🎙 #Podcast
In this episode, Prof. @JEscaned guides us through the “dark side of the moon” of #CAD — #INOCA, vasomotor disorders, and the underrecognized burden of non-obstructive #angina.
🔗https://t.co/7C1qdwdlGq
🎧https://t.co/ePIykhKVZW

#CardioEd #Atherosclerosis #Cardiology

[Troels Yndigegn MD PhD @YndigegnY]

Thank you for all the great feedback following the presentation of our novel fenestration technique at #EuroPCR2025 today!

Our approach was:
> Simple - anyone can learn
> Available - no specialized tools
> Fast - less than 5 minutes needed for all 14 operators to complete

[Troels Yndigegn MD PhD @YndigegnY]

Thanks a lot! The technique we developed uses a small balloon as support and inflated stent-balloon to “bounce” off at the level of the carina. We tested this method and found it was reproducible among 14 operators with different skill levels (6mo-20y) and also fastest.

[Christoffer H. Bach @ChrisHBach]

Good heart advice from my cardiologist friend @drandrewsharp.

[Andrew Sharp @drandrewsharp]

Why this approach is alluring but not how cardiovascular risk management should be done…. A thread🧵

[Christoffer H. Bach @ChrisHBach]

From CAD to ACAD! Potentially saving millions of lives.

[Davide Capodanno @DFCapodanno]

Our Commission, now published in The Lancet, advocates redefining coronary artery disease as atherosclerotic coronary artery disease (ACAD). This shift moves beyond the traditional ischemia-centered model to a systematic approach addressing atherosclerosis earlier. We believe this reframing will enable earlier identification and management, with the potential to save millions of lives worldwide.
Commission: https://t.co/u2FuonmrOz
Editorial: https://t.co/a9K6wzQqlJ
Comment: https://t.co/Z2xHctbIe5

[Ole Fröbert @FrobertOle]

Our 2021 IAMI flu vaccine trial continues to make waves - first shaping European guidelines with a 1A recommendation, now the same in the American version.
@SVRaoMD @Globalbiosec @mmamas1973 @MGtberg @drjohnm @DLBHATTMD @StabellBenn @cpgale3 @DrMarthaGulati @LGHemkens

[Gregg W. Stone MD @GreggWStone]

NEW! 2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Intravascular imaging guidance with OCT or IVUS during PCI in ACS is now recommended for left main or complex lesions with a class IA recommendation.

[Abdullah Al-Abcha @AbdullahAlabcha]

Check out this #JACCINT interview with @MGtberg discussing the long term #outcomes of #IFR vs #FFR guided #coronary revascularization; insights from the #SWEDEHEART registry🫀👇🏽

https://t.co/e9jTZDSY5d

@JACCJournals #CardioX #ACCFIT

[JACC Journals @JACCJournals]

This #JACCINT analysis of 42,887 patients from the #SWEDEHEART registry shows comparable rates of #MACE (31.3% vs. 32.2%) between IFR vs FFR-guided #PCI and no difference in all-cause mortality over 5 years. https://t.co/P0vATOsgpQ @MGtberg

[Matthias Götberg @MGtberg]

1/2 Finally we can share this now published analysis of iFR vs. FFR and outcome from Swedeheart registry.
In all 3 different models we find similar outcome. No signal of increased mortality. This should put the debate of between iFR and FFR at rest. https://t.co/BQa6VAzeX9

[Niels R. Holm @NielsRHolm]

Angiographic ambiguity and risk of inferior procedural results increases substantially with complexity - and so does the procedural and prognostic value of IVI.
But things can go wrong even in the simplest PCI - unnoticed by angiography.
So not using IVI in all procedures is just about procedural cost effectiveness.
If IVI catheters were cheap or did not affect the procedural costs - e.g. like the post PCI medical therapy - we would not have this discussion.

[Javier Escaned @JEscaned]

How does the presence of a CTO influence coronary physiology measurements in other vessels? What time-dependent physiological changes take place after successful CTO PCI? All this discussed in the article published today in @MyJSCAI Open access here: https://t.co/hp9o4gsA48

[Matthias Götberg @MGtberg]

@ColletCarlos @RAAnderson1 Well I truly commend the authors for completing this very complex trial. It’s however only 46 patients making discordance assessments difficult. We recently investigated outcomes in LMCA deferral in 1030 patients with no difference between iFR and FFR. https://t.co/44D0SrTanP